P7C3 is a laboratory-made molecule, neither supplement nor licensed medicine, developed to keep nerve cells alive. No person has knowingly received it in a published study. Treated animals consistently kept more nerve cells, but when the broader idea was tested in people using a widely sold nutrient, those taking it fared worse than placebo. For longevity-focused adults, an open research story: no dose, safety record or approved product for humans. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood NAD⁺ (energy-transfer coenzyme) metabolite panel | No established target; track change from own baseline | Expected to change; direct pathway output |
| ALT (alanine aminotransferase), with AST (aspartate aminotransferase) and bilirubin | ALT 7–56 U/L | Safety check; cleared by the liver, a rise would pause or stop use |
| Complete blood count with differential | Haemoglobin 13.5–17.5 g/dL (men), 12.0–15.5 g/dL (women); neutrophils 1.5–8.0 ×10⁹/L | Safety check; a falling count would stop use |
| Fasting glucose | 70–99 mg/dL | Expected to change; safety check for glucose falling too low |
| Plasma p-tau217 (a phosphorylated form of the tau protein) | No established target; track change from own baseline | Expected to change where brain injury or Alzheimer-type pathology is present |
Cadence: No human monitoring protocol exists; first-in-human logic: baseline, 1, 4 and 12 weeks, then every 3–6 months; earlier if any new symptom.